Rep. Gilbert Cisneros (D-CA) Buys COO Stock

Representative Gilbert Cisneros, a Democrat serving California's 31st district in the U.S. House, recently added to his investment portfolio with a purchase of The Cooper Companies, Inc. (COO) stock. According to a periodic transaction report filed under the STOCK Act on June 9, 2026, the trade occurred on May 29, 2026. The purchase was valued in a range between $1,001 and $15,000.

This transaction is one of several recent trades for the Congressman, who has been active in the healthcare and industrial sectors lately. In early May, he reported buying shares in firms like Sensata Technologies, Veralto Corporation, and STERIS plc. These disclosures are part of required transparency for members of Congress, who must report their financial moves shortly after they happen.

The Cooper Companies Stock Performance

On Saturday, shares of The Cooper Companies were priced at $72.14. This puts the stock right in the middle of its 52-week range, which spans from a low of $51.01 to a high of $89.83. The stock is currently trading slightly below its 200-day moving average of $72.43 but remains above its 50-day moving average of $69.61. With a price-to-earnings (P/E) ratio of 18.6, the market is valuing the company at about 18 times its trailing earnings. The company's forward P/E, which looks at projected future earnings, sits at 11.5.

Recent Earnings and Growth

The Cooper Companies reported revenue of $4.24 billion for its most recent period, showing a modest revenue growth of 0.6%. The company maintained a net margin of 13.46% and a return on equity of 6.8%. Investors looking ahead should note that the company is expected to release its next set of financial results on December 10, 2026.

Analysts Set New Price Targets

Wall Street firms have been adjusting their views on the medical device maker recently. On October 7, 2026, Barclays initiated coverage on the stock with an Equal-Weight rating and a $60.00 price target. Earlier, on September 15, 2026, Needham reiterated a Buy rating with a $73.00 target. However, several other analysts grew more cautious in September. Mizuho maintained an Outperform rating but cut its price target from $85.00 to $75.00 on September 11. Both Piper Sandler and William Blair downgraded the stock to Neutral or Market Perform ratings around the same time. The current consensus among 14 analysts is a Buy, with an average price target of $66.21.

Medical Devices and Vision Care

The Cooper Companies is a healthcare firm that focuses on two main areas: contact lenses and women's health. Through its CooperVision branch, it makes specialized contact lenses for people with astigmatism and other vision needs. Its CooperSurgical division provides medical devices and services for fertility, contraception, and family health. Based in San Ramon, California, the company employs roughly 15,000 people and sells its products to hospitals, clinics, and eye care professionals globally.

Future Outlook

Investors often watch politician trades for insight into which sectors or companies are attracting interest from lawmakers, though these filings are disclosed weeks after the actual trade. The next major catalysts for The Cooper Companies will likely be its upcoming earnings report in December and any further shifts in analyst price targets as the company navigates the competitive medical supply market.